Can an obese patient be normotensive?

Yes, Obese Patients Can Be Normotensive

Yes, normotensive obesity exists—obese individuals can have normal office blood pressure readings. However, this apparent "normotension" often masks underlying cardiovascular risk and subclinical blood pressure abnormalities that are not captured by standard office measurements 1, 2.

The Reality of "Normotensive" Obesity

While obesity is strongly associated with hypertension—with cardiovascular event rates nearly 50% higher in obese individuals compared to those with normal BMI 1—a subset of obese patients maintains office blood pressure readings within normal limits. This phenomenon is well-documented but clinically deceptive.

Hidden Cardiovascular Risk Despite Normal Office BP

Even when office blood pressure appears normal, obese patients demonstrate significant cardiovascular abnormalities:

• Ambulatory BP monitoring reveals elevated readings that office measurements miss. Normotensive obese patients show higher systolic and diastolic BP values on 24-hour monitoring, with increased daytime BP load correlating directly with rising BMI 3, 4

• Arterial stiffness is significantly increased in normotensive obese subjects (ambulatory arterial stiffness index 0.48 vs 0.33 in normal weight controls, p<0.001), indicating subclinical vascular damage 4

• Non-dipping pattern predominates in 66.4% of office-normotensive obese children and adolescents, representing abnormal circadian BP regulation that increases cardiovascular risk 3

• Left ventricular remodeling occurs independent of hypertension, particularly in metabolically unhealthy obese patients. Concentric remodeling and hypertrophy develop at rates comparable to hypertensive patients 5

Metabolic Health Status Matters

The distinction between metabolically healthy and metabolically unhealthy obesity is critical:

• Metabolically healthy normotensive obese patients show relatively low risk of left ventricular hypertrophy 5

• Metabolically unhealthy normotensive obese patients, those with type 2 diabetes, and especially those with both obesity and diabetes demonstrate LV remodeling at rates similar to hypertensive patients 5

• Obesity and type 2 diabetes have additive effects on cardiac remodeling even in normotensive patients 5

Underlying Mechanisms

Normotensive obese patients still exhibit pathophysiological changes that predispose to future hypertension:

• Sympathetic nervous system overactivity is present even with normal BP, with muscle sympathetic nerve activity significantly elevated (50.0 vs 32.9 bursts per 100 heart beats after weight loss) 6

• Baroreflex impairment occurs, reducing the body's ability to regulate BP appropriately 6

• Insulin resistance is present and contributes to vascular dysfunction 7

Clinical Implications and Management

Do not be falsely reassured by normal office BP in obese patients. The 2024 ESC Guidelines emphasize that visceral obesity is associated with incident hypertension, and even modest weight loss (5 kg) reduces systolic BP by 4.4 mmHg and diastolic BP by 3.6 mmHg 2.

Weight Loss Reverses Abnormalities

Evidence demonstrates that weight reduction in normotensive obese patients:

• Reduces sympathetic activity by 34% (from 50.0 to 32.9 bursts per 100 heart beats) 6
• Improves baroreflex sensitivity by 72-125% 6
• Lowers BP even when starting values are in the normotensive range (systolic BP reduced from 128 to 121 mmHg, diastolic from 75.4 to 69.6 mmHg) 7
• Improves arterial compliance in large arteries 7
• Enhances insulin sensitivity 6, 7

Recommended Approach

For normotensive obese patients, implement comprehensive obesity management as outlined in current guidelines 1:

1. Target 5-10% weight loss through multicomponent behavioral interventions (minimum 14 sessions over 6 months)

2. Consider anti-obesity medications for patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities, even if normotensive. GLP-1 receptor agonists (semaglutide, liraglutide) or tirzepatide are first-line options, with tirzepatide achieving 21% weight loss at 72 weeks 1

3. Use ambulatory BP monitoring rather than relying solely on office readings to identify masked hypertension and assess true cardiovascular risk 3, 4

4. Monitor pulse pressure as a convenient predictor of LV remodeling in normotensive obese patients 5

5. Screen for metabolic dysfunction (insulin resistance, dyslipidemia, glucose intolerance) as metabolically unhealthy obesity carries substantially higher cardiovascular risk even with normal BP 5

Critical Caveat

BMI alone should not determine individual risk 1. Use lower BMI thresholds for Asian populations (≥25-27.5) and assess metabolic health status, visceral adiposity, and cardiovascular risk factors comprehensively rather than relying on weight and office BP alone.